Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1

Chamutal Gur; Naseem Maalouf; Amjad Shhadeh; Orit Berhani; Bernhard B. Singer; Gilad Bachrach; Ofer Mandelboim

doi:10.1080/2162402X.2019.1581531

Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1

Chamutal Gur, Naseem Maalouf, Amjad Shhadeh, Orit Berhani, Bernhard B. Singer, Gilad Bachrach, Ofer Mandelboim^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

107 Scopus citations

Abstract

Fusobacterium nucleatum (F. nucleatum) is an oral anaerobe found to be enriched in colorectal cancer (CRC). Presence of F. nucleatum in CRC has been correlated with resistance to chemotherapy and poor prognosis. We previously demonstrated that the Fap2 outer-surface protein of F. nucleatum binds and activates the human inhibitory receptor TIGIT which is expressed by T and Natural Killer (NK) cells, and inhibits anti-tumor immunity. Here we show that F. nucleatum also binds and activates the human inhibitory receptor CEACAM1 leading to inhibition of T and NK cells activities. Our results suggest that using CEACAM1 and TIGIT inhibitors and specific targeting of fusobacteria should be considered for treating fusobacteria-colonized tumors.

Original language	English
Article number	e1581531
Journal	OncoImmunology
Volume	8
Issue number	6
DOIs	https://doi.org/10.1080/2162402X.2019.1581531
State	Published - 3 Jun 2019

Bibliographical note

Publisher Copyright:
© 2019, © 2019 Taylor & Francis Group, LLC.

Keywords

CEACAM1
Fusobacterium nucleatum
inhibition of killing

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/2162402X.2019.1581531

Cite this

@article{83d958fc032e43d58a40a7ece78aa8b0,

title = "Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1",

abstract = "Fusobacterium nucleatum (F. nucleatum) is an oral anaerobe found to be enriched in colorectal cancer (CRC). Presence of F. nucleatum in CRC has been correlated with resistance to chemotherapy and poor prognosis. We previously demonstrated that the Fap2 outer-surface protein of F. nucleatum binds and activates the human inhibitory receptor TIGIT which is expressed by T and Natural Killer (NK) cells, and inhibits anti-tumor immunity. Here we show that F. nucleatum also binds and activates the human inhibitory receptor CEACAM1 leading to inhibition of T and NK cells activities. Our results suggest that using CEACAM1 and TIGIT inhibitors and specific targeting of fusobacteria should be considered for treating fusobacteria-colonized tumors.",

keywords = "CEACAM1, Fusobacterium nucleatum, inhibition of killing",

author = "Chamutal Gur and Naseem Maalouf and Amjad Shhadeh and Orit Berhani and Singer, {Bernhard B.} and Gilad Bachrach and Ofer Mandelboim",

note = "Publisher Copyright: {\textcopyright} 2019, {\textcopyright} 2019 Taylor & Francis Group, LLC.",

year = "2019",

month = jun,

day = "3",

doi = "10.1080/2162402X.2019.1581531",

language = "אנגלית",

volume = "8",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "6",

}

TY - JOUR

T1 - Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1

AU - Gur, Chamutal

AU - Maalouf, Naseem

AU - Shhadeh, Amjad

AU - Berhani, Orit

AU - Singer, Bernhard B.

AU - Bachrach, Gilad

AU - Mandelboim, Ofer

PY - 2019/6/3

Y1 - 2019/6/3

N2 - Fusobacterium nucleatum (F. nucleatum) is an oral anaerobe found to be enriched in colorectal cancer (CRC). Presence of F. nucleatum in CRC has been correlated with resistance to chemotherapy and poor prognosis. We previously demonstrated that the Fap2 outer-surface protein of F. nucleatum binds and activates the human inhibitory receptor TIGIT which is expressed by T and Natural Killer (NK) cells, and inhibits anti-tumor immunity. Here we show that F. nucleatum also binds and activates the human inhibitory receptor CEACAM1 leading to inhibition of T and NK cells activities. Our results suggest that using CEACAM1 and TIGIT inhibitors and specific targeting of fusobacteria should be considered for treating fusobacteria-colonized tumors.

AB - Fusobacterium nucleatum (F. nucleatum) is an oral anaerobe found to be enriched in colorectal cancer (CRC). Presence of F. nucleatum in CRC has been correlated with resistance to chemotherapy and poor prognosis. We previously demonstrated that the Fap2 outer-surface protein of F. nucleatum binds and activates the human inhibitory receptor TIGIT which is expressed by T and Natural Killer (NK) cells, and inhibits anti-tumor immunity. Here we show that F. nucleatum also binds and activates the human inhibitory receptor CEACAM1 leading to inhibition of T and NK cells activities. Our results suggest that using CEACAM1 and TIGIT inhibitors and specific targeting of fusobacteria should be considered for treating fusobacteria-colonized tumors.

KW - CEACAM1

KW - Fusobacterium nucleatum

KW - inhibition of killing

UR - http://www.scopus.com/inward/record.url?scp=85063485117&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2019.1581531

DO - 10.1080/2162402X.2019.1581531

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 31069151

AN - SCOPUS:85063485117

SN - 2162-4011

VL - 8

JO - OncoImmunology

JF - OncoImmunology

IS - 6

M1 - e1581531

ER -

Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this